BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
Ralph Mueller 1
Christoph Schlag 2
Christoph Schmöcker 3
Roland Greinwald 1
Luc Biedermann 4
Michael Vieth 5
Alfredo J. Lucendo 6
Cecilio Santander 7
Alex Straumann
Petr Hruz
Ahmed Madisch
Stephan Miehlke
Stephen E. Attwood
Arjan Bredenoord
Stefan Schubert
Constanza Ciriza De Los Ríos
Alain M. Schoepfer
Jamal Hayat
Ulri
1 Dr. Falk Pharma GmbH,Freiburg,Germany
2 Klinikum rechts der Isar - TU München,München,Germany
3 Sana Klinikum Lichtenberg,Berlin,Germany
4 University Hospital Zurich,Zurich,Switzerland
5 Klinikum Bayreuth,Bayreuth,Germany
6 Hospital General de Tomelloso,Tomelloso,Spain
7 Hospital Universitario de la
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]